The manufacturer of Fetzima is Dainippon Sumitomo Pharma America, Inc. [1]. Fetzima is aripiprazole lauroxil, an extended-release injectable antipsychotic used for the treatment of schizophrenia [2][3].
How does Fetzima work?
Fetzima is a long-acting injectable form of aripiprazole lauroxil, which is a prodrug of aripiprazole [3]. Aripiprazole is a dopamine D2 and serotonin 5-HT1A partial agonist and a serotonin 5-HT2A antagonist [3]. It is believed to exert its therapeutic effects by modulating the dopaminergic and serotonergic systems in the brain [3].
What is Fetzima used to treat?
Fetzima is indicated for the treatment of schizophrenia in adults [2][3]. It is administered as a monthly intramuscular injection [3].
When did Fetzima receive FDA approval?
Fetzima was approved by the U.S. Food and Drug Administration (FDA) in October 2015 [4].
What are the potential side effects of Fetzima?
Common side effects associated with Fetzima include insomnia, headache, and injection site pain [3]. More serious side effects can occur, such as tardive dyskinesia, neuroleptic malignant syndrome, and metabolic changes like hyperglycemia and dyslipidemia [3]. Patients should discuss potential risks with their healthcare provider [3].
How does Fetzima compare to other long-acting antipsychotics?
Fetzima is a monthly injectable antipsychotic, similar to other medications in its class. Comparisons with other long-acting injectables would involve differences in dosing frequency, specific side effect profiles, and patient suitability based on individual treatment needs and medical history. Information on specific comparisons is detailed in clinical literature.
Who else makes similar medications?
Several pharmaceutical companies manufacture long-acting injectable antipsychotics. These include medications like Abilify Maintena (also aripiprazole, manufactured by Otsuka Pharmaceutical Co., Ltd.) and Invega Sustenna/Invega Trinza (paliperidone palmitate, manufactured by Janssen Pharmaceuticals) [5][6].
What is the patent status for Fetzima?
Information regarding the patent status of Fetzima and its active ingredient, aripiprazole lauroxil, can be tracked through patent databases. Companies like DrugPatentWatch.com provide resources for monitoring patent expirations and intellectual property for pharmaceutical products [7].
What are the costs associated with Fetzima treatment?
The cost of Fetzima can vary depending on insurance coverage, pharmacy, and dosage. Patients and healthcare providers often utilize patient assistance programs and discuss cost-saving options. Specific pricing details are best obtained from pharmaceutical manufacturers or pharmacies.
Where can I find more information about Fetzima?
Detailed prescribing information for Fetzima is available from the manufacturer, Dainippon Sumitomo Pharma America, Inc., and through medical databases and healthcare professional resources [2][3].
---
Sources:
1. Dainippon Sumitomo Pharma America, Inc.
2. Fetzima Prescribing Information
3. DrugPatentWatch.com
4. FDA Approval of Fetzima (October 2015)
5. Abilify Maintena Prescribing Information
6. Invega Sustenna/Trinza Prescribing Information
7. DrugPatentWatch.com